Search

Your search keyword '"Tricoci, P."' showing total 249 results

Search Constraints

Start Over You searched for: Author "Tricoci, P." Remove constraint Author: "Tricoci, P."
249 results on '"Tricoci, P."'

Search Results

1. Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation

2. IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial

3. Author Correction: IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial

5. Propuesta de nuevo modelo de caracterización de adopción de TIC en pymes argentinas

6. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

7. Patterns of conduct of Argentine SMEs with respect to ICT investments

9. Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial

10. Gobierno de TI y utilización de los sistemas de información en las firmas argentinas

12. INFORMATION TECHNOLOGY AND COMMUNICATIONS INVESTMENTS AND ITS IMPACT ON COMPETITIVENESS

13. INVERSIONES EN TECNOLOGÍAS DE LA INFORMACIÓN Y COMUNICACIONES Y SU IMPACTO EN LA COMPETITIVIDAD

14. Efficacy and Safety of Vorapaxar in Non–ST‐Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery

15. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

16. Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention

17. Un meta-análisis de los efectos de las TIC sobre el nivel de empleo y los roles laborales: comentarios y direcciones futuras

18. Una mirada sobre el impacto del uso de las redes sociales en las empresas argentinas

23. Effect of Alirocumab on Mortality After Acute Coronary Syndromes An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial

24. Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial

25. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

28. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

29. Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute...

30. Protease-Activated Receptor-1 Antagonists Post-Percutaneous Coronary Intervention

31. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

32. 3111Genetic variability in PAR4 platelet response in relation to bleeding and ischemic outcomes: a genetic substudy of the TRACER trial

33. The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction.

35. Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome.

36. Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention.

37. Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.

38. Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials

39. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

40. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes

42. Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome.

43. An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome.

45. Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute...

46. Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials.

Catalog

Books, media, physical & digital resources